Gerd R Burmester
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer A, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). J Clin Med 2022; 11
Dec 9, 2022Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Dec 9, 2022J Clin Med 2022; 11
Koehm Michaela, Foldenauer Ann C, Rossmanith Tanja, Alten Rieke, Aringer Martin, Backhaus Marina, Burmester Gerd R, Feist Eugen, Kellner Herbert, Krueger Klaus, Müller-Ladner Ulf, Rubbert-Roth Andrea, Tony Hans-Peter, Wassenberg Siegfried, Burkhardt Harald, Behrens Frank
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022
Nov 10, 2022EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Nov 10, 2022Ann Rheum Dis 2022
Smolen Josef S, Landewé Robert B M, Bergstra Sytske Anne, Kerschbaumer Andreas, Sepriano Alexandre, Aletaha Daniel, Caporali Roberto, Edwards Christopher John, Hyrich Kimme L, Pope Janet E, de Souza Savia, Stamm Tanja, Takeuchi Tsutomu, Verschueren Patrick, Winthrop Kevin, Balsa Alejandro, Bathon Joan M, Buch Maya H, Burmester Gerd R, Buttgereit Frank, Cardiel Mario Humberto, Chatzidionysiou Katerina, Codreanu Catalin, Cutolo Maurizio, den Broeder Alfons A, El Aoufy Khadija, Finckh Axel, Fonseca João Eurico, Gottenberg Jacques-Eric, Haavardsholm Espen A, Iagnocco Annamaria, Lauper Kim, Li Zhanguo, McInnes Iain B, Mysler Eduardo F, Nash Peter, Poór Gyula, Ristic Gorica G, Rivellese Felice, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Stoilov Nikolay, Strangfeld Anja, van der Helm-van Mil Annette, van Duuren Elsa, Vliet Vlieland Theodora P M, Westhovens René, van der Heijde Désirée
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Rubbert-Roth A, Furst D, Fiore S, Praestgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther 2022; 24:207.
Aug 25, 2022Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Aug 25, 2022Arthritis Res Ther 2022; 24:207
Rubbert-Roth Andrea, Furst Daniel E, Fiore Stefano, Praestgaard Amy, Bykerk Vivian, Bingham Clifton O, Charles-Schoeman Christina, Burmester Gerd R
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther 2021
Dec 30, 2021Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Dec 30, 2021Rheumatol Ther 2021
Burmester Gerd R, Liu John, Mccaskill Reva M, Lertratanakul Apinya, Lippe Ralph, Lesser Elizabeth, Rubbert-Roth Andrea, Salvarani Carlo, Azevedo Valderilio F, Goupille Philippe, Nash Peter, Blanco Ricardo, Winthrop Kevin, Ruderman Eric M
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Behrens F, Wassenberg S, Tony H, Rubbert-Roth A, Müller-Ladner U, Lehn A, Krueger K, Kellner H, Herrmann E, Feist E, Burmester G, Backhaus M, Aringer M, Alten R, Rossmanith T, Koehm M, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology (Oxford) 2021; 60:5318-5328.
Jan 3, 2021Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Jan 3, 2021Rheumatology (Oxford) 2021; 60:5318-5328
Behrens Frank, Wassenberg Siegfried, Tony Hans-Peter, Rubbert-Roth Andrea, Müller-Ladner Ulf, Lehn Annette, Krueger Klaus, Kellner Herbert, Herrmann Eva, Feist Eugen, Burmester Gerd R, Backhaus Marina, Aringer Martin, Alten Rieke, Rossmanith Tanja, Koehm Michaela, Burkhardt Harald
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
van der Heijde D, Mariette X, Li Z, Koloumas M, Huizinga T, Hetland M, Gottenberg J, Gossec L, Finckh A, Emery P, Müller-Ladner U, Mysler E, da Silva J, Westhovens R, Voshaar M, Takeuchi T, Strangfeld A, Saag K, Ruyssen-Witrand A, Rubbert-Roth A, Pope J, Poór G, van Eijk-Hustings Y, Edwards C, Cutolo M, de Wit M, van Vollenhoven R, Sepriano A, McInnes I, Kerschbaumer A, Dougados M, Burmester G, Bijlsma J, Landewé R, Aletaha D, Aringer M, Askling J, Codreanu C, De Cock D, Cardiel M, Caporali R, Buttgereit F, Buch M, den Broeder A, Boers M, Balsa A, Smolen J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685-699.
Jan 22, 2020EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Jan 22, 2020Ann Rheum Dis 2020; 79:685-699
van der Heijde Désirée, Mariette Xavier, Li Zhanguo, Koloumas Marios, Huizinga Tom W J, Hetland Merete Lund, Gottenberg Jacques-Eric, Gossec Laure, Finckh Axel, Emery Paul, Müller-Ladner Ulf, Mysler Eduardo F, da Silva Jose A P, Westhovens René, Voshaar Marieke, Takeuchi Tsutomu, Strangfeld Anja, Saag Kenneth G, Ruyssen-Witrand Adeline, Rubbert-Roth Andrea, Pope Janet E, Poór Gyula, van Eijk-Hustings Yvonne, Edwards Christopher John, Cutolo Maurizio, de Wit Maarten, van Vollenhoven Ronald F, Sepriano Alexandre, McInnes Iain B, Kerschbaumer Andreas, Dougados Maxime, Burmester Gerd R, Bijlsma Johannes W J, Landewé Robert B M, Aletaha Daniel, Aringer Martin, Askling John, Codreanu Catalin, De Cock Diederik, Cardiel Mario Humberto, Caporali Roberto, Buttgereit Frank, Buch Maya H, den Broeder Alfons A, Boers Maarten, Balsa Alejandro, Smolen Josef S
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Burmester G, Boklage S, St John G, Thangavelu K, Gervitz L, Pena-Rossi C, Gómez-Centeno A, Raskina T, Amital H, Rubbert-Roth A, Strand V, Genovese M. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open 2019; 5:e001017.
Oct 18, 2019Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Oct 18, 2019RMD Open 2019; 5:e001017
Burmester Gerd R, Boklage Susan, St John Gregory, Thangavelu Karthinathan, Gervitz Leon, Pena-Rossi Claudia, Gómez-Centeno Antonio, Raskina Tatiana, Amital Howard, Rubbert-Roth Andrea, Strand Vibeke, Genovese Mark C